Wells Fargo analyst Derek Archila raised the firm’s price target on Zymeworks (ZYME) to $14 from $12 and keeps an Overweight rating on the shares. The firm notes ZW49’s de-prioritizartion makes Zymeworks a pre-clinical story now, though Jazz Pharmaceuticals’ (JAZZ) March 19th R&D day, which will exclusively focus on zani opptys probably offers some upside for shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZYME:
- Zymeworks price target raised to $10 from $8 at H.C. Wainwright
- Zymeworks’ New Costs Risk – A Cause for Worry?
- Zymeworks files to sell 5.09M shares of common stock for holders
- Zymeworks price target raised to $21 from $19 at Stifel
- Zymeworks Poised for Growth with Strong Cash Position
Questions or Comments about the article? Write to editor@tipranks.com